ÁøÇ༺ ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚ¿¡¼ PemetrexedÀÇ È¿°ú¿Í ¾ÈÀü¼º
Efficacy and Safety of Pemetrexed in Advanced Non-Small Cell Lung Carcinoma
°áÇÙ¹×È£Èí±âÁúȯ 2009³â 67±Ç 2È£ p.121 ~ p.126
À̱ÔÁø(Lee Gyu-Jin) - °í½Å´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Á¤¸¸È«(Jung Maan-Hong) - °í½Å´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀåÅ¿ø(Jang Tae-Won) - °í½Å´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¿Áöȣ(Oak Chul-Ho) - °í½Å´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Á¤ÇöÁÖ(Jung Hyun-Joo) - °í½Å´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Background: Pemetrexed has been prescribed newly as a second line chemotherapy in advanced non-small cell lung carcinoma (NSCLC). The aim of study was to determine the efficacy and toxicity of pemetrexed in advanced NSCLC.
Methods: Patients with histologically or cytologically confirmed NSCLC were evaluated from June 2006 to December 2008. The patients had relapsed or progressed after prior chemotherapy treatment. They were treated with intravenous pemetrexed 500 mg/m2 for 10 min on Day 1 of each 21-day cycle.
Results: A total of 89 patients were eligible for analysis. The response rate and disease control rate were 11% and 66%. Non-squamous cell carcinoma histology was significantly associated with a superior response rate (p=0.035) and disease control rate (p=0.009) than squamous cell carcinoma histology. The median survival time was 13 months and the median progression free survival time was 2.3 months. The median survival time of patients with ECOG PS 0~1 was 13.2 months, whereas median survival time was 11.6 months for patients with PS 2 (p=0.002). The median progression free survival time of patients with PS 0~1 were 3.8 months, but 2.1 months for patients with PS 2 (p=0.016). The median progression free survival time of smokers with non-squamous cell carcinoma was 3.4 months, which was significant (p=0.014). Grade 3~4 neutropenia were seen in 7.9% patients.
Conclusion: Pemetrexed has efficacy in patients who had prior chemotherapy with advanced NSCLC and less hematologic toxicity.
Å°¿öµå
Pemetrexed, Non-small-cell lung carcinoma, Drug therapy
KMID :
0383820090670020121
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Pemetrexed has efficacy in patients who had prior chemotherapy with advanced NSCLC and less hematologic toxicity